In summary, our results highlight the complex role of CD38 in CTCL biology and stress the importance of identifying optimal drug combinations when used alongside CD38 antibodies for superior outcomes in CTCL patients. The gene discussed is CD38; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.